Your browser doesn't support javascript.
loading
Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke.
Zhong, Jun; Li, Rong-Wei; Wang, Ju; Wang, Ying; Ge, Hong-Fei; Xian, Ji-Shu; Feng, Hua; Tan, Liang.
Afiliação
  • Zhong J; Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing, China.
  • Li RW; Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing; Department of Neurosurgery, Hanzhong Central Hospital, Hanzhong, Shaanxi Province, China.
  • Wang J; Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing, China.
  • Wang Y; Department of Oncology, Hanzhong Central Hospital, Hanzhong, Shaanxi Province, China.
  • Ge HF; Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing, China.
  • Xian JS; Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing, China.
  • Feng H; Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing, China.
  • Tan L; Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University); State Key Laboratory of Power Transmission Equipment and System Security and New Technology, School of Electrical Engineering, Chongqing University, Chongqing, China.
Neural Regen Res ; 16(2): 312-318, 2021 Feb.
Article em En | MEDLINE | ID: mdl-32859790
ABSTRACT
Cattle encephalon glycoside and ignotin (CEGI) injection is known as a multi-target neuroprotective drug that contains numerous liposoluble molecules, such as polypeptides, monosialotetrahexosyl ganglioside (GM-1), free amino acids, hypoxanthine and carnosine. CEGI has been approved by the Chinese State Food and Drug Administration and widely used in the treatments of various diseases, such as stroke and Alzheimer's disease. However, the neuroprotective effects of CEGI beyond the time window of thrombolysis (within 4.5 hours) on acute ischemic stroke remain unclear. This study constructed a rat middle cerebral artery occlusion model by suture-occluded method to simulate ischemic stroke. The first daily dose was intraperitoneally injected at 8 hours post-surgery and the CEGI treatments continued for 14 days. Results of the modified five-point Bederson scale, beam balance test and rotameric test showed the neurological function of ischemic stroke rats treated with 4 mL/kg/d CEGI improved significantly, but the mortality within 14 days did not change significantly. Brain MRI and 2,3,5-triphenyltetrazolium chloride staining confirmed that the infarct size in the 4 mL/kg/d CEGI-treated rats was significantly reduced compared with ischemic insult only. The results of transmission electron microscopy and double immunofluorescence staining showed that the hippocampal neuronal necrosis in the ischemic penumbra decreased whereas the immunopositivity of new neuronal-specific protein doublecortin and the percentage of Ki67/doublecortin positive cells increased in CEGI-treated rats compared with untreated rats. Our results suggest that CEGI has an effective neuroprotective effect on ischemic stroke when administered after the time window of thrombolysis. The study was approved by the Animal Ethics Committee of The Third Military Medical University, China.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article